

Table S2. Patient outcomes at baseline, 12-months, and 24-months by 12-month injection interval subgroups using only patients with 24 months of follow-up data.

Factor	N	≤ q8w	N	q8-12w	N	>q12	P-value ¹
BVA (ETDRS), Mean ± SD							
Baseline	101	65.1±11.5	54	60.5±16.5	38	69.3±9.32	0.020
. 12 Month	101	68.8±12.1	54	68.9±10.4	38	70.9±8.4	0.83
Change from baseline	101	3.3±11.4	54	8.4±13.0	38	1.5±9.5	0.037
p-value ² (Baseline vs. 12 month)		0.004		1.74e-05		0.32	
. 24 Month	101	70.9±10.0	54	69.8±10.0	38	71.4±8.8	0.70
Change from baseline	101	5.4±11.7	54	9.3±15.4	38	2.0±12.3	0.10
p-value ² (Baseline vs. 24 month)		1.46e-05		4.69e-05		0.32	
CST (µm), Mean ± SD							
Baseline	101	414±98.5	54	446±122	38	436±118	0.30
. 12 Month	101	341±90.3	54	347±81.4	38	361±101	0.68
Change from baseline	101	-73.1±110	54	-98.8±128	38	-72.8±141	0.51
p-value ² (Baseline vs. 12 month)		1.76e-09		5.88e-07		3.28e-03	
. 24 Month	101	322±94.5	54	324±82.1	38	353±91.4	0.11
Change from baseline	101	-91.3±117	54	-122±142	38	-85.1±163	0.43
p-value ² (Baseline vs. 24 month)		1.13e-11		5.88e-08		0.0031	